LEO Pharma Open Innovation

Who should participate?

The LEO Pharma Open Innovation platform is basically open for any official institution or registered company with compounds, such as (but not limited to):

SMEs/Biotech companies – could be early compounds with relevant in vitro and/or in vivo results that could be of interest to LEO Pharma for e.g. in-licensing or collaborative drug discovery.

Research institutions – e.g. government or foundation sponsored research developing compounds for e.g. pharmacological explorations and target evaluation.

University groups – e.g. University department with compounds holding unique properties, both for pursuing concept and novel treatments.

Pharmaceutical companies – compound assets that could be out-licenced with a dermatological and skin inflammatory focus.